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Chronic white matter lesion activity predicts
clinical progression in primary progressive
multiple sclerosis
Colm Elliott,1,* Shibeshih Belachew,2,*,† Jerry S. Wolinsky,3 Stephen L. Hauser,4
Ludwig Kappos,5 Frederik Barkhof,6,7 Corrado Bernasconi,2 Julian Fecker,2 Fabian Model,2
Wei Wei2 and Douglas L. Arnold1,8
*These authors contributed equally to this work.
Chronic active and slowly expanding lesions with smouldering inflammation are neuropathological correlates of progressive multiple
sclerosis pathology. T1 hypointense volume and signal intensity on T1-weighted MRI reflect brain tissue damage that may develop
within newly formed acute focal inflammatory lesions or in chronic pre-existing lesions without signs of acute inflammation. Using a
recently developed method to identify slowly expanding/evolving lesions in vivo from longitudinal conventional T2- and T1-weighted
brain MRI scans, we measured the relative amount of chronic lesion activity as measured by change in T1 volume and intensity within
slowly expanding/evolving lesions and non-slowly expanding/evolving lesion areas of baseline pre-existing T2 lesions, and assessed the
effect of ocrelizumab on this outcome in patients with primary progressive multiple sclerosis participating in the phase III, randomized,
placebo-controlled, double-blind ORATORIO study (n = 732, NCT01194570). We also assessed the predictive value of T1-weighted
measures of chronic lesion activity for clinical multiple sclerosis progression as reflected by a composite disability measure including the
Expanded Disability Status Scale, Timed 25-Foot Walk and 9-Hole Peg Test. We observed in this clinical trial population that most of
total brain non-enhancing T1 hypointense lesion volume accumulation was derived from chronic lesion activity within pre-existing T2
lesions rather than new T2 lesion formation. There was a larger decrease in mean normalized T1 signal intensity and greater relative
accumulation of T1 hypointense volume in slowly expanding/evolving lesions compared with non-slowly expanding/evolving lesions.
Chronic white matter lesion activity measured by longitudinal T1 hypointense lesion volume accumulation in slowly expanding/
evolving lesions and in non-slowly expanding/evolving lesion areas of pre-existing lesions predicted subsequent composite disability
progression with consistent trends on all components of the composite. In contrast, whole brain volume loss and acute lesion activity
measured by longitudinal T1 hypointense lesion volume accumulation in new focal T2 lesions did not predict subsequent composite
disability progression in this trial at the population level. Ocrelizumab reduced longitudinal measures of chronic lesion activity such as
T1 hypointense lesion volume accumulation and mean normalized T1 signal intensity decrease both within regions of pre-existing T2
lesions identified as slowly expanding/evolving and in non-slowly expanding/evolving lesions. Using conventional brain MRI, T1-
weighted intensity-based measures of chronic white matter lesion activity predict clinical progression in primary progressive multiple
sclerosis and may qualify as a longitudinal in vivo neuroimaging correlate of smouldering demyelination and axonal loss in chronic
active lesions due to CNS-resident inflammation and/or secondary neurodegeneration across the multiple sclerosis disease continuum.
1 NeuroRx Research, Montreal, QC, Canada
2 F. Hoffmann-La Roche Ltd, Basel, Switzerland
3 McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA
4 University of California, San Francisco, San Francisco, CA, USA
5 University Hospital Basel, University of Basel, Basel, Switzerland
6 VU University Medical Centre, Amsterdam, The Netherlands
doi:10.1093/brain/awz212 BRAIN 2019: 142; 2787–2799 | 2787
Received December 5, 2018. Revised May 10, 2019. Accepted May 22, 2019.
 The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
7 UCL Institutes of Biomedical Engineering and Neurology, London, UK
8 McGill University, Montreal, QC, Canada
†Present address: Biogen, Cambridge, MA, USA
Correspondence to: Dr Colm Elliott
3575 Parc Avenue, Suite 5322, Montreal, QC, H2X 3P9, Canada
E-mail: celliott@neurorx.com
Keywords: MS: imaging; MS: biomarkers; MS: clinical trials; neuroinflammation; white matter lesion
Abbreviations: 9HPT = 9-Hole Peg Test; EDSS = Expanded Disability Status Scale; ITT = intention-to-treat; PPMS = primary
progressive multiple sclerosis; SEL = slowly expanding/evolving lesion; T25FW = Timed 25-Foot Walk
Introduction
While acute multiple sclerosis plaques predominate in pa-
tients with early relapsing multiple sclerosis and are the
likely substrate of clinical attacks, chronic active or smoul-
dering plaques are more prominent in patients with pro-
gressive multiple sclerosis (Kutzelnigg et al., 2005; Frischer
et al., 2015) and may expand as a result of sustained in-
flammatory processes driven by a rim of iron-laden micro-
glia/macrophages (Kutzelnigg et al., 2005; Frischer et al.,
2009, 2015; Bramow et al., 2010; Correale et al., 2017).
Pathological studies have shown that smouldering demye-
lination occurs in a similar extent in primary progressive
multiple sclerosis (PPMS) and secondary progressive mul-
tiple sclerosis (SPMS), and is associated with incomplete
remyelination resulting in irreparable myelin loss
(Bramow et al., 2010). In vivo, analysis of the natural his-
tory of new multiple sclerosis lesions using 7-T MRI has
shown that a persistent phase rim (which may reflect both
smouldering inflammation and the presence of iron-laden
microglia/macrophages) predicts poor tissue outcome with
lower quantitative T1 signal intensity over time (Absinta
et al., 2016a, b, 2018). These observations are consistent
with the concept of slowly expanding demyelination as a
pathological correlate of clinically progressive multiple
sclerosis (Prineas et al., 2001).
Recently, we developed a method for automatic detection
of chronic active or slowly expanding/evolving lesions
(SELs) on conventional brain MRI as a potential read-out
of ‘smouldering’ or chronic active plaques (Elliott et al.,
2018a, b). We defined SELs as contiguous regions of pre-
existing T2 lesions that show local constant and concentric
expansion as assessed by the Jacobian determinant of the
non-linear deformation between reference and follow-up
scans. SELs were shown to be devoid of T1 gadolinium
(Gd)-enhancement, had a lower mean T1 signal intensity
at baseline and showed a more severe pattern of further
progressive decrease in T1 intensity over time, as compared
with non-SEL areas of pre-existing lesions (Elliott et al.,
2018a, b). The constant decrease in T1 signal intensity of
SELs was consistent with the expected T1-weighted MRI
behaviour of smouldering plaques, as the core of such le-
sions is typically characterized by severe accumulation of
axonal damage (Kornek et al., 2000; Frischer et al., 2009).
Thus, SELs may qualify as a potential read-out for progres-
sive accumulation of irreversible neural tissue damage and
especially axonal loss (van Walderveen et al., 1998; Filippi
et al., 2012). These observations are also consistent with
pathological and proton magnetic resonance spectroscopy
studies showing that the magnitude of tissue destruction
and, in particular, axonal loss, was reflected by the de-
crease in T1-weighted signal intensity within multiple scler-
osis lesions (van Waesberghe et al., 1999; van Walderveen
et al., 1999; Filippi et al., 2012). Several observational
cohort studies suggested that cross-sectional multiple scler-
osis lesion burden and longitudinal change in overall lesion
counts and volume may predict long-term disability accu-
mulation in patients with PPMS (Sastre-Garriga et al.,
2005; Khaleeli et al., 2008; Rocca et al., 2017).
However, those studies relied on relatively limited sample
sizes and did not address the underlying role of chronic
multiple sclerosis lesion activity.
Here we examined the respective contributions of new
acute lesion formation versus chronic lesion activity to
the accrual of T1 hypointense lesion volume, in the PPMS
study population of the ORATORIO trial. We assessed the
effect of ocrelizumab versus placebo on the accrual of T1
hypointense lesion volume related to chronic lesion activity.
Finally, we evaluated whether T1-weighted conventional
brain MRI measures of chronic lesion activity predicted
disability outcomes along the natural history of PPMS dis-
ease course in the placebo arm from ORATORIO.
Materials and methods
Trial design, clinical endpoints and
MRI acquisition specifications
All analyses were performed in the phase III, randomized, pla-
cebo-controlled, double-blind, multicentre ORATORIO trial
(NCT01194570). ORATORIO study details have been re-
ported previously (Montalban et al., 2017). Key eligibility cri-
teria included an age of 18 to 55 years, diagnosis of PPMS
(2005 revised McDonald criteria) (Polman et al., 2005) and an
Expanded Disability Status Scale (EDSS) score of 3.0 to 6.5 at
screening. Patients (n = 732) were randomized (2:1) to receive
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either ocrelizumab 600mg by intravenous infusion every 24
weeks or placebo every 24 weeks for 5120 weeks until a
prespecified number of 12-week confirmed disability progres-
sion events occurred. After the primary data-cut, patients re-
mained on randomized treatment (controlled treatment phase)
until the outcome of the trial was evaluated and patients were
eligible for open-label ocrelizumab treatment (open-label ex-
tension phase). Patients who completed the controlled treat-
ment phase received randomized treatment for at least 144
weeks and up to 240 weeks. All clinical assessments in the
double-blind controlled period of ORATORIO trial were per-
formed 12-weekly. As described in the ORATORIO primary
outcome results (Montalban et al., 2017), the assessments of
12-week confirmed disability progression endpoints were per-
formed in a time-to-first event analysis, in which disability in-
crease had to be sustained on subsequent visits for at least 12
weeks. A composite measure of disability progression was used
in primary intent for the analysis of the clinical predictive
value of chronic versus acute white matter lesion activity and
brain atrophy. Composite disability progression outcome in-
cludes measures of hand/arm function and ambulation speed
and provides a more comprehensive capture of change in the
totality of disability features (Bosma et al., 2009; Cadavid
et al., 2017), especially in progressive forms of multiple scler-
osis. Furthermore, composite disability progression has re-
cently been used as a primary endpoint in randomized
controlled trials in patients with PPMS (Lublin et al., 2016)
and SPMS (Kapoor et al., 2018).
Standardized conventional brain MRI was performed at
baseline and Weeks 24, 48 and 120 in the ORATORIO
trial. Axial 3mm T1-weighted slices (3D spoiled gradient-
echo, repetition time = 28–30ms, echo time = 5–11ms, flip
angle = 27–30) were acquired pre- and post-Gd injection
(0.1mmol/kg, 10-min post-injection delay). Axial 3mm T2-
weighted slices were acquired with 2D fast spin-echo, repeti-
tion time = 4000–6190ms, echo time = 74–91ms and echo
train length = 7–11. The original 1mm  1mm  3mm
image resolution was resampled into a 1-mm isotropic space
as a first step of the SEL Jacobian analysis detection pipeline
(Nakamura et al., 2013), which was described previously
(Elliott et al., 2018a, b). Both T1-weighted and T2-weighted
images were used for detection of SELs. The T1-weighted
signal was normalized using least trimmed squares (LTS)
over time for a given patient, followed by tissue-based normal-
ization, where 0 and 1 values represent median T1 signal inten-
sities of normal-appearing grey and white matter, respectively.
Identification of overall T2
hyperintense lesions, T1 hypointense
lesions and new focal T2 lesions
Overall, T2 lesions were identified on baseline scans using a
semi-manual approach, where an initial automatic segmenta-
tion of T2 hyperintense lesions (Francis, 2004) was manually
corrected by trained readers. The automatic detection of T2-
hyperintense lesions was performed using a Bayesian classifier
that provides probabilistic tissue classification at each voxel
based on multi-sequence MRI intensities and on atlas-derived
prior probabilities of healthy tissue classes (white matter, grey
matter and CSF) and T2-hyperintense lesion, based on spatial
location in a standard template [International Consortium for
Brain Mapping (ICBM)] space (Francis, 2004). T1 hypointense
lesions were identified as the subset of T2 hyperintense lesions
that (i) were more T1 hypointense than median grey matter
based on voxel-level analysis of absolute T1 signal intensity;
and (ii) did not show Gd-enhancement on a post-contrast T1-
weighted scan. New or enlarging T2 lesions were identified
based on differences in T2 lesion segmentations at reference
and follow-up time points, with post-processing to remove
spurious difference due to segmentation variability and misre-
gistration, and on subsequent manual review by trained read-
ers. New or enlarging T2 lesion detection provides a marker for
acute focal inflammation in multiple sclerosis. The algorithm
used to detect ‘enlargement’ in ‘new or enlarging’ T2 lesion
segmentation was designed to detect new foci of activity con-
fluent with pre-existing T2-lesion, as well as obvious concentric
lesion growth during the acute stage of new lesion formation.
More subtle and gradual chronic enlargement/evolution within
pre-existing T2 lesions was intentionally not captured.
Identification of slowly expanding/
evolving lesions
The method for the identification of SELs using the T1-weighted
and T2-weighted images simultaneously has been described pre-
viously (Elliott et al., 2018a, b). Briefly, SELs are identified
(based on MRI scans obtained at baseline and at post-baseline
Weeks 24, 48 and 120) as areas of pre-existing T2 lesions of at
least 10 contiguous voxels (voxel size is 3 mm3) showing
gradual and constant concentric expansion. Identification of
SELs was carried out using a two-stage process. First, the
Jacobian determinant of the non-linear deformation field is
computed between the reference and follow-up scans, to quan-
tify subtle and gradual change in pre-existing T2 lesions
(Nakamura et al., 2013). Contiguous regions of the baseline
pre-existing T2 lesions undergoing local expansion are identified
as SEL candidates, which are subsequently heuristically scored,
to favour those undergoing concentric and constant change,
consistent with gradual inside-out radial expansion. Results per-
taining to the analyses of SELs will be presented for all SEL
candidates (regions of pre-existing T2 lesion undergoing local
expansion, regardless of heuristic score; ‘SELs’), and high-con-
fidence SELs (with a heuristic score 50; ‘high-confidence SELs’)
(Elliott et al., 2018a, b). SEL identification and all T1-weighted
measures related to SELs and non-SELs were performed by
NeuroRx Research who remained blinded to all study patient-
level and treatment assignment information.
Normalization of T1 signal intensity
Prior to measuring T1 intensity change over time, T1-weighted
images were normalized in a two-stage process: (i) LTS was
used to normalize all subsequent (in time) T1-weighted images
of a given subject to the baseline T1-weighted scan; and (ii) T1-
weighted images for a given subject were linearly normalized
by mapping the median grey matter T1 intensity at baseline to
a value of zero, and mapping the median normal-appearing
white matter intensity at baseline to 1. LTS performs linear
regression between co-registered sequential scans using the
50% of voxels whose least squares fit possesses the smallest
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sum of squared residuals (Rousseeuw et al., 2006). This has
the effect of normalizing intensities within a given subject
based only on the subset of voxels that remain relatively un-
changed over time.
The first stage of normalization ensures a common intensity
space across time for a given subject, while the second stage
provides comparable measures of T1 intensity change across
different subjects.
Statistical analysis
The statistical analysis of SEL data was exploratory and
included all patients from ORATORIO with no missing or
non-evaluable MRI scans (SEL analysis population). Mean
changes in T1 and T2 lesion volume were calculated as
power means of cube root transformed data. No imputation
of missing data was performed, except for the analysis of the
change of T1 hypointense volume, where for patients from the
SEL analysis population who did not have any SELs, the SEL-
associated T1 hypointense volume and its change from baseline
were imputed as zero.
A Wilcoxon rank-sum test for continuous variables and
Fisher’s exact test for categorical variables were applied to
compare baseline characteristics between two treatment
groups (ocrelizumab and placebo) for both the intention-to-
treat (ITT) and SEL analytical populations.
Identification of SELs and the change of longitudinal predict-
ive factors were calculated based on data from the first 120
weeks after randomization. To avoid misinterpretation in infer-
ring the direction of causal dependence, clinical outcomes were
re-baselined at Week 120 and only data after Week 120 until
the end of the controlled period was used to evaluate the effect
of chronic lesion activity, acute lesion activity and whole brain
atrophy on disability progression outcomes. The survival ana-
lysis of predictive factors for clinical endpoints employed Cox
regression models, including the predictive factors of interest,
and stratified for region (rest of world, US) and age (545
years, 545 years). The comparison of continuous variables
by lesion sector (SELs, non-SELs, total T2 burden and new T2
lesions) was performed using the Van Elteren test, stratified for
treatment group (ocrelizumab, placebo) and baseline T2 lesion
volume category based on tertiles (43.013 cm3,53.013 cm3 to
411.122 cm3, and 411.122 cm3). Longitudinal analyses of
lesion counts and volumes used negative binomial regression
and linear mixed models for repeated measures, respectively.
Statistical tests were two-sided and conducted at the 5% signifi-
cance level without adjustment for multiplicity.
Data availability
Qualified researchers may request access to individual pa-
tient level data through the clinical study data request plat-
form (www.clinicalstudydatarequest.com). Further details on
Roche’s criteria for eligible studies are available at https://clin-
icalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roc
he.aspx. Further details on Roche’s Global Policy on the shar-
ing of clinical information and how to request access to related
clinical study documents, are available at https://www.roche.
com/research_and_development/who_we_are_how_we_work/cl
inical_trials/our_commitment_to_data_sharing.htm.
Results
Baseline demographics and
characteristics of the ORATORIO
PPMS study population
Baseline demographics and MRI characteristics were well
balanced between the ITT and SEL analytical populations
(Table 1). There was a minor imbalance in the mean
number of T1 Gd-enhancing lesions in the ITT population
between the ocrelizumab and placebo treatment groups,
which is slightly larger in the SEL analytical population.
Overall, T2 and T1 lesion volume was higher in the ocre-
lizumab-treated patients in both the ITT and SEL analyt-
ical populations, with the difference being more
pronounced in the SEL analytical population.
Importantly, there was no numerical imbalance between
the T1/T2 lesion volume ratio between the two treatment
arms. All between-group differences were non-significant
in the ITT and SEL analytical populations (all P-values
40.05; Table 1).
Increase in non-enhancing T1
hypointense lesion volume occurs
mostly within pre-existing T2 lesions
An increase in non-enhancing T1 hypointense lesion
volume was seen in both the ocrelizumab arm and the
placebo arm, with a reduced T1 lesion volume increase
from baseline to Week 120 with ocrelizumab as compared
with placebo (P5 0.001) (Fig. 1A). In the ocrelizumab
group, we observed a continued increase in non-enhancing
T1 hypointense lesion volume from baseline to Week 120
(Fig. 1A), despite a decrease in T2 lesion volume (Fig. 1B)
and near absence of new focal T2 lesion formation (Fig.
1C). In the placebo group, T2 lesion volume increased
from baseline to Week 120 (Fig. 1B), and although there
was continued formation of new T2 lesions, the overall
absolute increase in non-enhancing T1 hypointense lesion
volume was larger by more than 2-fold that of T2 lesion
volume from baseline to Week 120 (cf. Fig. 1A and B).
These findings show that T1 hypointense lesion volume
increase in the ORATORIO PPMS population was
mostly driven by chronic lesion activity in T2 lesions pre-
existing at baseline, with a minimal impact of new or
enlarging T2 lesions in both treatment groups (Fig. 3).
Chronic brain tissue damage as measured by increasing
non-enhancing T1 hypointense lesion volume may largely
occur independently from new T2 lesion formation,
thereby reflecting chronic T1 signal intensity decrease
within pre-existing baseline T2 lesions, as illustrated by
the visual example shown in Fig. 1D.
2790 | BRAIN 2019: 142; 2787–2799 C. Elliott et al.
Chronic lesion activity measured by
T1 lesion volume change in SELs and
non-SEL areas
We have shown previously (Elliott et al., 2018a, b) that a
proportion of total pre-existing T2 lesion volume in the
ORATORIO study population could be identified as SEL
candidates and high-confidence SELs, while the rest of pre-
existing T2 lesions were defined as non-SEL areas. Hence,
we introduced a three-compartment model to further ad-
vance the understanding of the origin of overall T1 hypoin-
tense lesion volume accumulation, which may stem either
from ‘chronic’ lesion activity in (i) SELs; (ii) non-SEL areas
within boundaries of pre-existing T2 lesions (Fig. 2); or
(iii) from ‘acute’ lesion activity by new/enlarging T2 lesion
formation outside of the baseline T2 lesion boundaries.
SEL candidates were identified as 5.1% and 7.1% of pre-
existing T2 lesion volume in ocrelizumab- and placebo-trea-
ted patients, respectively, while high-confidence SELs (with
a score 50) represented 2.5% and 3.4% of pre-existing T2
lesion volume for ocrelizumab and placebo patients, re-
spectively. While accounting for a relatively small fraction
of pre-existing T2 lesions, proportionally, SELs accounted
for a much higher amount of T1 hypointense lesion volume
accumulation from baseline to Week 120 in both the ocre-
lizumab and placebo populations (Fig. 3).
Longitudinal profile of T1-weighted
measures of chronic lesion activity
The longitudinal by-patient (volume-normalized) analysis of
change from baseline to Week 120 in normalized T1 signal
intensity showed a lower T1 intensity at baseline
(Supplementary Fig. 5) and a greater decrease in T1 inten-
sity in SEL regions as compared with non-SEL regions
(Fig. 4) both in ocrelizumab and placebo-treated PPMS pa-
tients. High-confidence SELs (with a score 50) also
showed a slightly greater T1 intensity decrease than all
SEL candidates (Fig. 4) in both treatment arms.
Chronic lesion activity in pre-existing
T2 lesions predicts clinical PPMS
progression
Table 2 shows a comparison of the predictive value of
baseline T1 lesion volume burden versus chronic lesion ac-
tivity measured by longitudinal change in T1-weighted
lesion volume in pre-existing lesions (SELs and non-SELs),
respectively, from study baseline and from Week 120 to the
end of the controlled treatment period in the placebo group
of the ORATORIO trial. Baseline T1 lesion volume only
predicted clinical progression at the level of upper extrem-
ity function defined by a 12-week confirmed 520% in-
crease in 9-Hole Peg Test (9HPT) time [hazard ratio
(95% confidence interval, CI): 1.75 (1.08, 2.84);
P = 0.024] (Table 2, Supplementary Fig. 1A, G, M and
S). T1 lesion volume re-baselined at Week 120 had no sig-
nificant effect for any of the disability endpoints but
showed a similar pattern of higher hazard ratio for 9HPT
progression (data not shown). By contrast, longitudinal
chronic lesion activity from baseline to Week 120 as
measured by T1 lesion volume accumulation in (i) total
pre-existing T2 lesions (SELs and non-SELs); (ii) all
SEL candidates; (iii) SELs (with a score 50); and
Table 1 Baseline demographics and disease characteristics for the ITT and SEL analytical populations of the
ORATORIO trial
Baseline demographics and disease characteristics ITT population (n = 732) SEL analytical population (n = 555)
Placebo
(n = 244)
Ocrelizumab
(n = 488)
Placebo
(n = 171)
Ocrelizumab
(n = 384)
Age, mean (SD), years 44.4 (8.3) 44.7 (7.9) 45.0 (8.1) 44.9 (7.8)
Female, n (%) 124 (50.8) 237 (48.6) 88 (51.5) 188 (49.0)
Time since multiple sclerosis symptom onset, mean (SD), years 6.1 (3.6)a 6.7 (4.0)b 5.9 (3.3)c 6.6 (3.9)d
EDSS, mean (SD) 4.7 (1.2) 4.7 (1.2)e 4.6 (1.2) 4.6 (1.2)f
MRI
Number of T1 Gd-enhancing lesions, mean (SD) 0.6 (1.5)
g 1.2 (5.1)h 0.4 (1.2) 1.2 (5.5)f
Proportion of patients with 51 T1 Gd-enhancing lesion (%) 24.7
g 27.5h 21.1 27.2f
Brain T2 hyperintense lesion volume, median (range), cm
3 6.2 (0–81.1)g 7.3 (0–90.3)i 5.5 (0–59.2) 7.4 (0–82.4)f
Brain non-enhancing T1 hypointense lesion volume, median
(range), cm3
1.7 (0–35.4)g 2.0 (0–64.4)h 1.5 (0–35.4) 2.1 (0–53.5)f
T1/T2 lesion volume ratio, median (range) 0.32
g (0; 0.69) 0.32h (0; 0.77) 0.31 (0; 0.69) 0.32 (0; 0.77)
Normalized brain volume, mean (SD), cm3 1469.9 (88.7)g 1462.9 (84.0)j 1469.2 (86.3) 1459.3 (84.5)k
Cortical grey matter volume, mean (SD), cm3 542.1 (48.9)g 534.9 (55.1)j 543.7 (47.7) 534.6 (55.7)k
White matter volume, mean (SD), cm3 786.7 (54.8)g 787.9 (52.1)j 784.1 (51.8) 784.9 (50.0)k
All between-group differences were tested non-significant (all P-values4 0.05, Wilcoxon rank-sum test for continuous data and Fisher’s exact test for categorical data).
SD = standard deviation.
an = 237. bn = 474. cn = 165. dn = 373. en = 487. fn = 383. gn = 243. hn = 484. in = 486. jn = 482. kn = 379.
Chronic lesion activity in PPMS BRAIN 2019: 142; 2787–2799 | 2791
Figure 1 Chronic brain tissue damage as measured by increasing non-enhancing T1 hypointense lesion volume is reduced by
ocrelizumab and may occur independently from new T2 lesion formation. (A) Change in total non-enhancing T1 lesion volume
a. (B)
Change in total T2 lesion volume. (C) New focal T2 lesion formation. (D) Chronic brain tissue damage mostly occurs within pre-existing T2
lesions. An animated version of D is more appropriate for data visualization and is available in the Supplementary material. OCR = ocrelizumab;
T1w = T1-weighted.
aThe analysis of total non-enhancing T1 lesion volume was based on a T1 hypointense lesion threshold definition (as per pre-
specified ORATORIO study protocol) that was subsequently optimized for all T1 lesion volume analyses performed. Estimates and P-values are
from a mixed-effect model of repeated measures using an unstructured covariance matrix. bRates and P-values are from a negative binomial model
adjusted for baseline T2 lesion count, geographic region (rest of world, US) and age (445 years, 445 years).
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(iv) non-SELs, significantly predicted clinical progression
(from Week 120 to end of study) on 12-week confirmed
composite disability progression [12-week confirmed dis-
ability progression as measured by EDSS, or 12-week con-
firmed 520% increase in Timed 25-Foot Walk (T25FW)
time, or 12-week confirmed 520% increase in 9HPT time]
[hazard ratio (95% CI): (i) 2.32 (1.38,3.90), P = 0.001; (ii)
1.98 (1.20,3.28), P = 0.008; (iii) 1.87 (1.13,3.08),
P = 0.015; (iv) 2.20 (1.32,3.67), P = 0.003] with consistent
numerical trends on all components of the disability
burden (EDSS, T25FW and 9HPT) (Table 2 and
Supplementary Fig. 1). In comparison, longitudinal whole
brain volume loss from baseline to Week 120 did not pre-
dict clinical progression from Week 120 to end of study on
either component of the disability burden nor on composite
confirmed disability progression, with only a numerical
trend observed for progression of T25FW (Supplementary
Fig. 2). Similarly, acute white matter lesion activity from
baseline to Week 120 as measured by T1 lesion volume ac-
cumulation in new focal T2 lesions did not predict clinical
progression from Week 120 to end of study on either com-
ponent of the disability burden nor on composite confirmed
disability progression, with only a numerical trend observed
for progression of 9HPT (Table 2 and Supplementary Fig. 1).
It is important to emphasize that all placebo group ana-
lyses performed to evaluate the clinical predictive value of
imaging phenotypes were strictly devoid of ocrelizumab in-
fluence since the clinical outcome analysis was performed
from Week 120 to the end of the controlled period. A
switch of all placebo-treated patients to ocrelizumab treat-
ment only happened beyond the end of the controlled
period at the beginning of the open-label extension phase,
which was not integrated to the current analysis. Hence, all
the findings presented are not confounded by unblinding or
ocrelizumab treatment-related changes.
Accumulation of T1 hypointense
lesion volume in pre-existing T2
lesions is reduced by ocrelizumab
While an increase in T1 hypointense lesion volume was seen
in both the ocrelizumab and the placebo arm, T1 lesion
volume increase from baseline to Week 120 was reduced
with ocrelizumab compared with placebo (P50.001)
(Fig. 1A). Accumulation of T1 hypointense volume was
reduced with ocrelizumab as compared with placebo in
both pre-existing T2 lesions (P = 0.001) (Fig. 3) and in
acute new T2 lesions (P5 0.001) (Fig. 3). While the great-
est relative effect of ocrelizumab compared with placebo
was seen on T1 hypointense lesion volume increase asso-
ciated with acute new T2 lesion formation (P5 0.001),
proportionally, this was a minor contributor to overall T1
hypointense lesion volume accumulation (Fig. 3). If we con-
sider SEL and non-SEL regions of pre-existing T2 lesion
separately, ocrelizumab showed a reduction in T1 volume
increase for both compartments of chronic lesion activity
(non-SEL: P = 0.001, SEL: P5 0.001) (Fig. 3). The analysis
of the treatment effect over time showed a significant sep-
aration favouring ocrelizumab versus placebo in terms of
accumulation of T1 hypointense volume as of Week 48
within all SEL candidates, high-confidence SELs (with a
score 50), and non-SELs (Supplementary Fig. 3). To con-
firm that the effect of ocrelizumab on SELs was irrespective
of the heuristic threshold for high-confidence SELs, we
Figure 2 T1 hypointense volume accumulation may occur in SELs showing longitudinal expansion and in non-SEL areas of
pre-existing baseline T2 lesions. In this example, effectively all T1 hypointense lesion volume accumulation in this slice occurs within baseline
T2 lesions. An animated version of this figure is more appropriate for data visualization and is available in the Supplementary material.
T1w = T1-weighted; T2w = T2-weighted.
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performed a lesion-level analysis that showed consistent bene-
fits of ocrelizumab with respect to T1 hypointense volume
accumulation in SEL candidates above all tested thresholds
of heuristic SEL score distribution (Supplementary Fig. 4).
Since T1 hypointense volume accumulation analysis, by
definition, may not capture potential changes pertaining to
lesion voxels maintaining a T1 intensity superior to the
defined T1 hypointense threshold (median of normal-ap-
pearing grey matter), or pertaining to lesion voxels with
continued decrease in T1 intensity beyond this threshold,
we also assessed the effect of ocrelizumab versus placebo
on chronic lesion activity as measured by the volume-nor-
malized T1 signal intensity (mean T1 intensity of the voxels
constituting a lesion). The longitudinal analysis of the ab-
solute change from baseline to Week 120 in normalized T1
signal intensity in SELs showed a reduced decrease in T1
intensity in ocrelizumab-treated patients (ocrelizumab
versus placebo: –0.20 versus –0.24, P = 0.005) (Fig. 4B).
The same finding was observed in high-confidence SELs
(with a score 50) (ocrelizumab versus placebo: –0.24
versus –0.28, P = 0.013) (Fig. 4C), and in non-SEL regions
(ocrelizumab versus placebo: –0.05 versus –0.09,
P = 0.003) (Fig. 4D).
In comparison with these chronic lesion activity features
of SELs, the overall prevalence of SELs was not impacted
greatly by ocrelizumab versus placebo. The proportion of
patients with ‘all SEL candidates’ detected from baseline to
Week 120 was similar in the two treatment arms (ocreli-
zumab versus placebo: 85.2% versus 83.6%), as was the
proportion of patients with high-confidence SELs [with a
score 50 (73.2% versus 69.0%)]. However, ocrelizumab-
treated patients had a lower proportion of total pre-existing
T2 lesion identified as SEL candidates (median 5.1 versus
7.1%, P5 0.001) and high-confidence SELs [with a score
50 (median 2.5 versus 3.4%, P = 0.044)], from baseline to
Week 120.
Discussion
Our results indicate that in patients with PPMS the increase
in overall T1 lesion volume burden is mostly due to chronic
lesion activity leading to the accumulation of tissue damage
within pre-existing lesions and that T1-weighted measures
of chronic lesion activity are predictive of clinical PPMS
progression. We also showed that ocrelizumab, which is
highly effective in silencing acute new lesion formation in
early relapsing multiple sclerosis (Hauser et al., 2017) and
PPMS (Montalban et al., 2017), also reduced the relative
volume of SELs and T1-weighted in vivo measures of
chronic lesion activity in SELs and in non-SEL areas of
pre-existing lesions in patients with PPMS.
Although smouldering inflammation with sustained
macrophage/microglia activation and secondary neurode-
generation may intrinsically drive ongoing myelin/axonal
damage within chronic active multiple sclerosis lesions
(Frischer et al., 2015; Absinta et al., 2016a, b; Dal-
Bianco et al., 2017), it is also expected that acute multiple
sclerosis lesion activity could influence the CNS milieu and
indirectly impact the severity of chronic lesion activity fea-
tures. In the specific context of the ORATORIO trial popu-
lation, as much as 73.5% of the PPMS population had
MRI signs of acute multiple sclerosis lesion activity (T1
Gd-enhancing lesions and/or new focal T2 lesions) based
on results from the longitudinal analysis of the placebo
group from baseline to Week 120 (Wolinsky et al.,
2018). Nonetheless, the ocrelizumab-mediated near com-
plete suppression of acute multiple sclerosis lesion forma-
tion, as observed especially beyond treatment Week 48, did
not prevent a continued concurrent decrease in T1 signal
intensity and increase in T1 hypointense lesion volume
within SEL and non-SEL regions of chronic pre-existing
lesions. Those data show that chronic white matter mul-
tiple sclerosis lesion activity may evolve largely independ-
ently from acute (focal) inflammatory activity. However,
Figure 3 T1 hypointense lesion volume change from
baseline to Week 120 by lesion type and treatment group.
Box-and-whisker plots: box displays the quartiles; asterisks repre-
sent the mean values; bars represent the median values; whiskers
extend from the lowest datum5 1.5  lower quartile IQR to the
highest datum4 1.5 IQR upper quartile + IQR; range of values in
placebo/ocrelizumab, respectively: pre-existing T2 burden: 0.46–
12.90/6.23–24.54; non-SELs: 0.68–8.71/6.61–17.65; all SELs:
0.02–5.29/0.07–6.89; new T2 lesions: 0–3.36/0–1.18.
IQR = interquartile range; OCR = ocrelizumab. aVan Elteren test
stratified by treatment group (ocrelizumab, control) and baseline T2
lesion volume category based on tertiles. n = the number of patients
evaluable at Week 120. bFor each patient the sum change from
baseline in T1 volume of evaluable lesions was calculated. Missing
changes from baseline in volume are imputed to zero.
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the separation of T1-weighted measures of chronic lesion
activity between the placebo and ocrelizumab groups was
also most prominent beyond treatment Week 48. This ob-
servation suggests that the mechanism of ocrelizumab treat-
ment effect on chronic lesion activity may be partially and
indirectly explained by its potency to silence acute new
lesion formation and by-product release of mediators that
may participate in the activation of pro-inflammatory
macrophages/microglia, the core engine of chronic active
lesion pathology (Frischer et al., 2015).
Figure 4 T1-weighted intensity measures of chronic white matter lesion activity from baseline to Week 120. (A) Total baseline
T2 lesion burden. (B) All SEL candidates. (C) SELs (with a score50). (D) Non-SELs. Asterisks represent the median values. OCR = ocrelizumab.
aVan Elteren test stratified by treatment group (ocrelizumab, control) and baseline T2 lesion volume category based on tertiles. n = the number
of patients with at least one SEL at each visit. Volume normalization is calculated as: sum(SEL_volume  SEL_intensity) / sum(SEL_volume):
SEL volume is based on baseline T2 volume of SELs. For each patient, the sum relative change from baseline in T1 lesion volume of SELs
was calculated and this value was then summarized for the ITT population. bn-values at Week 120 for all panels. Reproduced from Elliott
et al. (2018a).
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This study of a large-scale PPMS clinical trial placebo
dataset also showed that at the population level T1-
weighted measures of chronic lesion activity predict clinical
PPMS progression measured by the composite of the three
major physical disability outcomes (EDSS, 9HPT and
T25FW) with consistent trends on all components, while
the baseline chronic lesion burden measured by total T1
lesion volume only predicted 9HPT outcome. In contrast
to chronic white matter lesion activity, the measures of
acute lesion activity did not predict subsequent disability
progression in this PPMS clinical trial population. These
results are consistent with previous retrospective analyses
of observational cohorts (Sastre-Garriga et al., 2005;
Khaleeli et al., 2008; Rocca et al., 2017) where the effect
of acute versus chronic lesion activity was not disentangled.
Importantly, longitudinal whole brain volume loss in
ORATORIO did not predict composite clinical disability
progression or its components, with only a numerical
trend with respect to ambulation progression as measured
by T25FW. ORATORIO findings further suggest that
chronic lesion activity is the major driver of overall accu-
mulation of lesion-related CNS tissue loss, and that recent
chronic lesion activity may carry more clinically predictive
information than recent brain atrophy or the overall base-
line lesion volume, which may principally reflect disease
duration and history. However, the overall cumulative
burden of chronic lesion activity is obviously related to
total multiple sclerosis lesion volume, and it was previously
shown in another major PPMS phase III trial population
that the rate of whole brain volume loss was strongly pre-
dicted by the baseline lesion volume burden but not by
other factors [e.g. number of Gd-enhancing lesions at base-
line (Miller et al., 2018)]. It was also shown in the latter
study that a higher lesion burden predicted brain volume
loss in the specific subgroup of patients with no signs of
acute lesion activity at baseline (Miller et al., 2018). The
value of in vivo longitudinal T1-weighted measures of
chronic lesion activity in SELs and non-SELs as surrogates
for clinical efficacy remains to be investigated and com-
pared with that of measures of acute lesion activity in pro-
gressive multiple sclerosis clinical trial datasets using
multivariate analysis.
A limitation of this study is that we cannot claim inde-
pendence of the clinical predictive value of T1-weighted
in vivo longitudinal measures of chronic lesion activity, as
(apart for stratification for T2 volume) our analysis models
could not include other potentially relevant predictors due
to the small number of clinical events post-Week 120. The
confirmation of our findings in other PPMS trial datasets
will be important as false positive results cannot be
excluded in our exploratory analysis that did not correct
for multiple testing. Another limitation is the absence of
spinal cord evaluation by MRI, which was not part of
the acquisition protocol in this study. The entire dynamic
of multiple sclerosis lesion formation and natural history,
as well as the potential involvement of smouldering or
slowly expanding demyelination at the spinal cord level,
remain less characterized in multiple sclerosis pathology.
However, it is known that chronic lesions in the spinal
cord are more likely to be inactive and less likely to be
smouldering compared with brain supratentorial lesions
(Frischer et al., 2015). Another limitation is the present
incapacity using exclusively conventional T1- and T2-
weighted imaging data to disentangle the contribution of
smouldering inflammation versus Wallerian secondary neu-
rodegeneration with respect to T1 intensity decrease in SELs
and non-SELs. A recently initiated study (CONSONANCE;
NCT03523858) will further address this question by as-
sessing the association between the SEL phenotype and
paramagnetic rims on susceptibility-based MRI or with
metabolic changes or axonal/neuronal damage measured
by spectroscopic magnetic resonance. Efforts are ongoing
to characterize the potential neuro-pathological correlates
of SELs in relation to that of paramagnetic rim lesions.
The origin and natural history of chronic multiple scler-
osis lesion activity detected through the SEL phenotype
based on longitudinal in vivo demonstration of chronic
lesion expansion or using other definitions, such as the
presence of a persistent phase rim, remains to be explored.
In particular the dynamics of demyelination and potential
remyelination (if at all occurring) cycles remains to be char-
acterized in the context of chronic active white matter le-
sions, e.g. using magnetization transfer and diffusion-based
imaging methods. It is also unknown whether newly
formed multiple sclerosis lesions at some point along their
lifespan may eventually and secondarily adopt the proper-
ties of chronic active lesions such as SELs. Notwithstanding
that this is an assumption through generalization of obser-
vations from scattered studies, there is a consensus that all
newly formed multiple sclerosis lesions are presumably
having an ‘acute’ phase at inception (Absinta et al.,
2016a, b; Guttmann et al., 2016). Some of those newly
formed multiple sclerosis lesions are also characterized by
an early phase rim, due to accumulation of paramagnetic
substances possibly corresponding to myelin-breakdown
compounds (Deh et al., 2018) and/or attendant infiltration
by blood-derived monocytes/macrophages (Absinta et al.,
2016a, b) and their related by-products. In approximately
half of those new acute lesions with centripetal contrast
enhancement, the early phase rim will vanish while T1
hypointensity may partially resolve, whereas in the other
half, the early phase rim may persist and T1 signal intensity
may continue to decrease (Absinta et al., 2016a, b).
Whether some of the newly formed multiple sclerosis le-
sions and likely those with an early persistent phase rim
may convert into chronic active lesions or be chronic active
with SEL properties from their inception remains to be
explored.
The observation that the depletion of CD20-expressing
cells similarly reduced chronic lesion activity both in pre-
existing T2 lesion areas with (SELs) or without (non-SELs)
signs of slow longitudinal expansion raises questions as to
the potential identity of the biological mechanisms at play
in both compartments. We noted a sizeable difference in
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the magnitude of T1-weighted measures of chronic lesion
activity in SEL and non-SEL areas of patients with PPMS,
but the lower grade of chronic lesion activity in non-SELs
remained significantly reduced by ocrelizumab. These data
are consistent with the pathological description (Frischer
et al., 2009) of the presence of inflammatory cellular infil-
trates (i.e. CD20+ B cells, CD3+ T cells and HLA-D-posi-
tive macrophages and microglia cells) in chronic inactive
lesions of patients with progressive multiple sclerosis, al-
though at lower density compared with that of ‘smoulder-
ing’ or ‘slowly expanding lesions’ but at higher density than
in the normal-appearing white matter (except for HLA-D-
positive macrophages and microglia cells). The results of
this work may indicate a potential role of CD20-expressing
cells in the chronic inflammatory processes leading to on-
going tissue damage in SELs or chronic ‘active’ lesions as
well as in previously termed chronic ‘inactive’ lesions or
non-SELs as studied herein. Whether a continuum of
chronic inflammatory pathology may also affect the
normal-appearing brain tissue might be ultimately assessed
using more advanced measures of tissue integrity.
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